Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mefloquine
Drug ID BADD_D01369
Description Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.[L30618] Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin.[L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche.[A226838] This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Indications and Usage For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
Marketing Status Prescription; Discontinued
ATC Code P01BC02
DrugBank ID DB00358
KEGG ID D04895
MeSH ID D015767
PubChem ID 4046
TTD Drug ID D0GQ7K
NDC Product Code Not Available
Synonyms Mefloquine | Mephloquine | WR-177,602 | WR 177,602 | WR177,602 | Ro-21-5998-001 | Ro 21 5998 001 | Ro215998001 | WR-142,490 | WR 142,490 | WR142,490 | Lariam | Mefloquine Hydrochloride
Chemical Information
Molecular Formula C17H16F6N2O
CAS Registry Number 49752-90-1
SMILES C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anxiety19.06.02.002--
Aplastic anaemia01.03.03.002--Not Available
Arthralgia15.01.02.001--
Arthropod bite12.01.08.022--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrioventricular block02.03.01.002--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Breast feeding26.05.01.001--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Cataract06.06.01.001--
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.003--Not Available
Chills15.05.03.016; 08.01.09.001--
Coma17.02.09.001--Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Conduction disorder02.03.01.008--
Confusional state19.13.01.001; 17.02.03.005--
Coordination abnormal17.02.02.004--Not Available
Deafness04.02.01.001--Not Available
Dermatitis23.03.04.002--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages